176
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Possible Role of TGF-β1, MMP-2, E-CAD, β-Catenin and Antioxidants in Pathogenesis of Placenta Accreta

, , , , &
Pages 222-232 | Received 24 Aug 2020, Accepted 16 Oct 2020, Published online: 11 Nov 2020
 

Abstract

Objectives Placenta accreta (PA) can be life-threatening due to postpartum hemorrhage and may lead to cesarean hysterectomy. We investigated the expression of Matrix metalloproteinase-2 (MMP-2), β-catenin, E-cadherin (E-CAD), transforming growth factor β1 (TGF-β1), glutathione peroxidase 1 (GPx-1), reduced glutathione (GSH) and superoxide dismutase (SOD) in PA compared to controls to determine if alterations may contribute to PA. Materials and methods: Twenty six PA and 31 controls were evaluated immunohistochemically for expression of MMP-2, β-catenin and E-CAD on villous and extravillous trophoblasts. TGF-β1 and GPx-1 mRNA levels were evaluated by rt-PCR. We measured biochemical levels of GSH and SOD. Results: Significant increases of MMP-2 immunoexpression, GPx-1 mRNA, SOD and GSH levels, decreases in immunoexpression of E-CAD and β-catenin and TGF-β1 mRNA were found in PA. Conclusion: These findings suggest that loss of cell-cell adhesion and increased antioxidants level may have a role in PA.

Disclosure statement

The author reported no conflict of interests regarding the publication of this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.